Vytrus BiotechXMAD:VYT +0.57%69 PEG Ratio is 1.20 as of Jul. 09, 2026, which is 167% above its 10-year median of 0.45. GuruFocus rates XMAD:VYT with a GF Score™ of 69/100 and a GF Value™ of €5.54 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 94 Biotechnology companies, Vytrus Biotech ranks better than 62.77% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Vytrus Biotech's PEG Ratio or its related term are showing as below:
XMAD:VYT'
s PEG Ratio Range Over the Past 10 Years
Min: 0.28 Med: 0.45 Max: 1.41
Current: 1.2
During the past 8 years, Vytrus Biotech's highest PEG Ratio was 1.41. The lowest was 0.28. And the median was 0.45.
XMAD:VYT's PEG Ratio is ranked better than 62.77% of 94
companies
in the Biotechnology industry
Industry Median: 1.98
vs XMAD:VYT: 1.20
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Vytrus Biotech (XMAD:VYT) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Vytrus Biotech PEG Ratio Related Terms
Vytrus Biotech PEG Ratio Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:VYT vs VRTX, REGN, ALNY: PEG Ratio Comparison
For the Biotechnology subindustry, Vytrus Biotech's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Vytrus Biotech (XMAD:VYT) has a PEG Ratio of 1.20 as of Jul. 09, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Vytrus Biotech and its competitors. This is 167% above median its historical median of 0.45. Over the past decade, Vytrus Biotech's PEG Ratio has ranged from 0.28 to 1.41. According to the industry distribution chart, Vytrus Biotech ranks #35 out of 94 companies in the Biotechnology industry, placing it in the top 37.2%.
Is Vytrus Biotech's PEG Ratio too high?
Vytrus Biotech's current PEG Ratio of 1.20 is 167% above median its 10-year median of 0.45. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 1.41. The Biotechnology industry median PEG Ratio is 1.98. Vytrus Biotech's value of 1.20 is 39.4% below this industry median. Based on the distribution chart, Vytrus Biotech ranks #35 out of 94 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vytrus Biotech has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #35 out of 94 companies for PEG Ratio. This puts Vytrus Biotech in the upper half of its industry. The industry median PEG Ratio is 1.98. Vytrus Biotech's value of 1.20 is 39.4% below this benchmark. Historically, Vytrus Biotech's own PEG Ratio has ranged from 0.28 to 1.41 over the past decade. While the company's 10-year median is 0.45 vs. the industry median of 1.98, Vytrus Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.98, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vytrus Biotech's current PEG Ratio of 1.20 is 39.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Vytrus Biotech and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current PEG Ratio is 1.20, which is 167% above median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.54, compared to a current price of €17.50 — trading 215.9% above its estimated fair value. The current PEG Ratio is 1.20, which is 167% above median its 10-year median of 0.45 and 39.4% below the Biotechnology industry median of 1.98. Vytrus Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current PEG Ratio is 1.20 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €17.50 is trading 215.9% above its estimated GF Value™ of €5.54.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
PEG Ratio: 1.20 (167% above median its 10-year median of 0.45)
GF Value™: €5.54 vs. price of €17.50 (215.9% above fair value)
Industry Position: 39.4% below the Biotechnology median (#35 of 94)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
69GF Score
Get the complete analysis for XMAD:VYT
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
